Registry for patients with Chronic Lymphocytic Leukemia in Austria
AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry
This study is collecting health information from people with Chronic Lymphocytic Leukemia in Austria to see how they are doing over time without changing their usual treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie Academic / other |
| Drugs / interventions | rituximab, cyclophosphamide, fludarabine |
| Locations | 9 sites (Feldkirch and 8 other locations) |
| Trial ID | NCT06250465 on ClinicalTrials.gov |
What this trial studies
This observational registry collects and analyzes medical, testing, and treatment data from patients diagnosed with Chronic Lymphocytic Leukemia (CLL) across multiple centers in Austria. It aims to gather longitudinal follow-up information, including survival rates and tumor progression, by extracting data from existing patient medical charts. The registry does not require any additional diagnostic or therapeutic measures beyond routine care, ensuring that participation does not interfere with standard treatment protocols. Patient confidentiality is maintained through unique identifiers assigned upon enrollment.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults aged 18 and older diagnosed with Chronic Lymphocytic Leukemia.
Not a fit: Patients who are not diagnosed with CLL or are under 18 years of age will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of CLL progression and treatment outcomes, ultimately improving patient care.
How similar studies have performed: Other observational registries in hematology have shown success in improving patient outcomes and understanding disease progression, indicating that this approach is both valid and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The registry will include patients ≥ 18 years with CLL. Exclusion Criteria: * There are no specific exclusion criteria.
Where this trial is running
Feldkirch and 8 other locations
- Landeskrankenhaus Feldkirch, Innere Med. II, Interne E — Feldkirch, Austria (Recruiting)
- Univ.-Klinik für Innere Medizin V, Hämatologie/Onkologie LKH-Innsbruck / Universitätskliniken — Innsbruck, Austria (Recruiting)
- A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie — Kufstein, Austria (Recruiting)
- KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie — Linz, Austria (Recruiting)
- Ordensklinikum Linz GmbH - Barmherzige Schwestern; Interne I: Medizinische Onkologie und Hämatologie — Linz, Austria (Recruiting)
- Ordensklinikum Linz GmbH, Elisabethinen, I. Interne Abteilung Hämato-Onkologie — Linz, Austria (Recruiting)
- UK Salzburg, LKH: Universitätsklinik für Innere Medizin III — Salzburg, Austria (Recruiting)
- Univ.-Klinikum St. Pölten, Innere Medizin 1 — Sankt Pölten, Austria (Recruiting)
- Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV — Wels, Austria (Recruiting)
Study contacts
- Principal investigator: Richard Greil, MD — Department of internal Medicine III, Paracelsus Medical University Salzburg, Austria
- Study coordinator: Daniela Wolkersdorfer
- Email: office@agmt.at
- Phone: +43 662 640 44 12
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.